120 Participants Needed

Light Therapy for Eczema

(BRONTE Trial)

KL
Overseen ByKaren Lau
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Women's College Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing two types of light therapy to find out which is better for treating eczema. It focuses on patients who haven't had success with other treatments. The light therapy helps by reducing skin inflammation and repairing the skin barrier.

Will I have to stop taking my current medications?

You may need to stop certain medications before joining the trial. If you're using phototherapy, oral immune-modulating drugs, or systemic biologics, you must stop them 30 to 90 days before starting. However, topical, intralesional, or inhaled corticosteroids are allowed.

Is light therapy safe for treating eczema?

Light therapy, including both broadband and narrowband UVB, is generally considered safe for treating skin conditions like eczema, but there is some concern about a potential increased risk of skin cancer with narrowband UVB.12345

How is light therapy for eczema different from other treatments?

Light therapy for eczema, specifically using narrowband UVB (NB-UVB), is unique because it uses a specific wavelength of ultraviolet light to reduce inflammation and improve skin conditions. This treatment is particularly effective for moderate to severe cases and is often used when other treatments have not worked well.12367

What data supports the effectiveness of the treatment for eczema?

Narrowband ultraviolet B (NB-UVB) therapy is a well-established and effective treatment for eczema, as well as other skin conditions like psoriasis and vitiligo. Studies suggest that NB-UVB is more effective than broadband UVB (BB-UVB) for these conditions.12367

Who Is on the Research Team?

AM

Aaron M Drucker

Principal Investigator

Women's College Hospital

Are You a Good Fit for This Trial?

This trial is for people with moderate to severe eczema who haven't improved after using topical treatments. They must meet specific criteria for eczema severity and have not used certain medications like systemic biologics, corticosteroids, or immune-modulating agents recently.

Inclusion Criteria

My condition is severe despite using creams or ointments.
Your doctor has determined that your condition is severe, scoring 3 or 4 out of 4.
I have been diagnosed with atopic dermatitis.
See 1 more

Exclusion Criteria

I haven't taken biologic or experimental drugs in the last 90 days.
I haven't taken immune-modulating drugs or had phototherapy in the last 30 days.
I haven't taken oral or intramuscular steroids in the last 30 days.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either Narrowband or Broadband UVB phototherapy three times weekly

12 weeks
36 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Broadband UVB phototherapy
  • Narrowband UVB phototherapy
Trial Overview The study compares two types of UVB phototherapy: Narrowband and Broadband, to see which one better improves eczema symptoms. Participants will be randomly assigned to receive one of these treatments as part of the larger CACTI study on skin health.
How Is the Trial Designed?
2Treatment groups
Active Control
Group I: Narrowband UVBActive Control1 Intervention
Group II: Broadband UVBActive Control1 Intervention

Broadband UVB phototherapy is already approved in Canada, United States, European Union for the following indications:

🇨🇦
Approved in Canada as Broadband UVB phototherapy for:
🇺🇸
Approved in United States as Broadband UVB phototherapy for:
🇪🇺
Approved in European Union as Broadband UVB phototherapy for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Women's College Hospital

Lead Sponsor

Trials
108
Recruited
43,700+

University of British Columbia

Collaborator

Trials
1,506
Recruited
2,528,000+

McGill University Health Centre/Research Institute of the McGill University Health Centre

Collaborator

Trials
476
Recruited
170,000+

University of Toronto

Collaborator

Trials
739
Recruited
1,125,000+

Published Research Related to This Trial

Narrowband ultraviolet B (nbUVB) phototherapy is a safe and effective treatment for children with atopic eczema, achieving complete or near-complete clearance in 52% of treated children, particularly those with higher skin phototypes (III to VI).
The treatment demonstrated high clinical remission rates at various follow-up intervals (100% at 0 months, 87% at 3 months, 57% at 6 months, and 52% at 12 months), with mild side effects reported in 28% of patients, suggesting it is a preferable second-line option over oral systemic treatments.
Treatment of paediatric eczema with narrowband ultraviolet light B therapy.Hunjan, MK., Brockley, JR., Buka, R., et al.[2021]
Narrowband ultraviolet B (NB-UVB) treatment resulted in a 61% reduction in eczema severity (measured by the SASSAD score) in 29 children, compared to a 6% increase in severity in a control group of 26 children who did not receive treatment.
The benefits of NB-UVB treatment not only improved objective eczema scores but also significantly enhanced quality of life, with effects lasting for at least 6 months post-treatment.
Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study.Darné, S., Leech, SN., Taylor, AE.[2022]
In a randomized controlled trial involving 73 adult patients with moderate to severe atopic eczema, narrow-band UVB phototherapy significantly reduced disease activity and extent of disease compared to visible light, with mean reductions of 9.4 points and 6.7%, respectively.
Narrow-band UVB was found to be well tolerated, with only a small number of patients experiencing mild side effects like erythema or eczema flare-ups, indicating its safety as an adjunctive treatment.
Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial.Reynolds, NJ., Franklin, V., Gray, JC., et al.[2015]

Citations

Treatment of paediatric eczema with narrowband ultraviolet light B therapy. [2021]
Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. [2022]
Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. [2015]
Phototoxicity of narrowband ultraviolet (UV) B (311 nm) compared with broadband UVB in the photo hen's egg test. [2016]
Narrow-band ultraviolet B treatment for vitiligo, pruritus, and inflammatory dermatoses. [2021]
Possible clinical efficacy and tolerability of platelet-rich plasma with atopic dermatitis. [2021]
The challenge of follow-up in narrowband ultraviolet B phototherapy. [2016]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security